Oral GnRH Antagonist Ovarian Suppression After Escape From GnRH Agonist in Breast Cancer Patients

Ovarian suppression with gonadotropin-releasing hormone (GnRH) agonists has been shown to be effective as an adjuvant therapy for patients with early-stage breast cancer.1 Recent randomized clinical trials have analyzed the effect of ovarian suppression among premenopausal women with estrogen receptor (ER)-positive breast cancers who retained ovarian function after chemotherapy treatment.2